Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Lehmann

Showing results (521-530 of 532) with videos related to

Pageof 54
Sort By:
Molecular Oncology|August 7, 2013
SPARCL1 suppresses metastasis in prostate cancerYuzhu Xiang, Qingchao Qiu, Ming Jiang, et al.
International Journal of Pediatric Otorhinolaryngology|November 11, 2023
Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccinesA J Leach, N Wilson, B Arrowsmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast CancerBrian D Lehmann, Vandana G Abramson, Melinda E Sanders, et al.
Cancer Discovery|October 4, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast CancerBrandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, et al.
Science Translational Medicine|March 13, 2020
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitorsJohanna M Schafer, Brian D Lehmann, Paula I Gonzalez-Ericsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Frontiers in Physiology|October 25, 2017
Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor RuxolitinibSvantje Sobotta, Andreas Raue, Xiaoyun Huang, et al.
Journal of Medicinal Chemistry|March 30, 2026
Identification of KLHL12 Ligands Using Fragment-Based MethodsAlex G Waterson, Anish Vadukoot, Somnath Jana, et al.
Cancer Discovery|December 21, 2013
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targetsJustin M Balko, Jennifer M Giltnane, Kai Wang, et al.
Cancer Research Communications|April 30, 2024
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast CancerElizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson, et al.
Pageof 54

Showing results (521-530 of 532) with videos related to

Sort By:
Pageof 54
Molecular Oncology|August 7, 2013
SPARCL1 suppresses metastasis in prostate cancerYuzhu Xiang, Qingchao Qiu, Ming Jiang, et al.
International Journal of Pediatric Otorhinolaryngology|November 11, 2023
Otitis media at 6-monthly assessments of Australian First Nations children between ages 12-36 months: Findings from two randomised controlled trials of combined pneumococcal conjugate vaccinesA J Leach, N Wilson, B Arrowsmith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR<sup>+</sup> Metastatic Triple-Negative Breast CancerBrian D Lehmann, Vandana G Abramson, Melinda E Sanders, et al.
Cancer Discovery|October 4, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast CancerBrandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, et al.
Science Translational Medicine|March 13, 2020
Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitorsJohanna M Schafer, Brian D Lehmann, Paula I Gonzalez-Ericsson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
Frontiers in Physiology|October 25, 2017
Model Based Targeting of IL-6-Induced Inflammatory Responses in Cultured Primary Hepatocytes to Improve Application of the JAK Inhibitor RuxolitinibSvantje Sobotta, Andreas Raue, Xiaoyun Huang, et al.
Journal of Medicinal Chemistry|March 30, 2026
Identification of KLHL12 Ligands Using Fragment-Based MethodsAlex G Waterson, Anish Vadukoot, Somnath Jana, et al.
Cancer Discovery|December 21, 2013
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targetsJustin M Balko, Jennifer M Giltnane, Kai Wang, et al.
Cancer Research Communications|April 30, 2024
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast CancerElizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson, et al.
Pageof 54